BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering
June 24, 2020 09:20 ET
|
BioSig Technologies, Inc.
Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several...
ViralClear Partners with Catalent on Potential Treatment for COVID-19
June 22, 2020 14:30 ET
|
BioSig Technologies, Inc.
Westport, CT, June 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has...
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19
June 17, 2020 07:55 ET
|
BioSig Technologies, Inc.
Westport, CT, June 17, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has...
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19
June 08, 2020 15:02 ET
|
BioSig Technologies, Inc.
Westport, CT, June 08, 2020 (GLOBE NEWSWIRE) -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be...
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
June 05, 2020 09:10 ET
|
BioSig Technologies, Inc.
Westport, CT, June 05, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc., today...
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions
June 04, 2020 09:25 ET
|
BioSig Technologies, Inc.
Westport, CT, June 04, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
BioSig Technologies Expands Intellectual Property Portfolio
June 03, 2020 11:45 ET
|
BioSig Technologies, Inc.
Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) -- U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals,...
ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19
June 01, 2020 10:42 ET
|
BioSig Technologies, Inc.
Westport, CT, June 01, 2020 (GLOBE NEWSWIRE) -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be...
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
May 28, 2020 08:40 ET
|
BioSig Technologies, Inc.
Westport, CT, May 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board of Directors of its...
ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
May 20, 2020 10:12 ET
|
BioSig Technologies, Inc.
Westport, CT, May 20, 2020 (GLOBE NEWSWIRE) -- Funding completed in subsidiary without dilution to BioSig common stockPhase II human trials for merimepodib, a broad-spectrum oral anti-viral...